ArticleBMC cancer2026
Adebrelimab plus chemotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESCC): a single-center, phase II, single-arm, open-label clinical trial (ADENEO) protocol.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06452602 (Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Stratified Exploratory Phase 2 Trial.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
introductionWhile radical chemoradiotherpy (CRT) is the standard treatment for patients with unresectable locally advanced esophageal squamous cell carcinoma (LA-ESCC), the prognosis remains extremely poor. Although combining CRT with immunotherapy benefits a subset of patients with advanced disease, recurrence and metastasis after treatment are still common. The overall response rate (ORR) of induction chemoimmunotherapy (ICI) for advanced esophageal cancer is approximately 40%-70%. Radiotherapy or concurrent chemoradiotherapy after induction of chemoradiation is more effective. This study aims to tailor subsequent treatment based on the response to ICI to improve therapeutic efficacy for LA-ESCC. METHODS AND ANALYSIS: The ADENEO trial is a single center, phase II, single-arm, open-label clinical trial that will enroll 60 patients. Eligible patients will be registered, enrolled and receive 2 cycles of adebrelimab plus albumin paclitaxel and carboplatin, and the efficacy will be evaluated. Patients will be divided into two groups according to the efficacy of induction therapy: complete response + partial response (CR + PR) group and stable disease + progression disease (SD + PD) group. In the CR + PR group, patients will be treated with CCRT combined with adebrelimab. The radiotherapy dose is planning target volume (PTV): 50.4 Gy/1.8 Gy/28F. Chemoimmunotherapy will consist of adebrelimab plus albumin-bound paclitaxel and carboplatin, followed by adebrelimab maintenance for up to one year. Patients in the SD + PD group will receive CCRT alone. The radiotherapy dose is PTV/planned gross tumor volume (PGTV): 50.4 Gy/59.92 Gy/28F. The chemotherapy regimen will change to FOLFOX regimen (oxaliplatin, tetrahydrofolic acid and 5-FU) and immunotherapy will not be used during CRT because of tolerance to previous immunotherapy. The primary endpoint is the progression free survival (PFS) assessed by the investigators, and the secondary endpoints are ORR, overall survival (OS), duration of response (DoR), adverse event (AE) and serious adverse time (SAE). ETHICS AND DISSEMINATION: Written informed consent will be obtained from all patients enrolled. The study protocol been approved by the Independent Ethical Committee of Tianjin Medical University Cancer Institute & Hospital. The final manuscript will be submitted for publication upon completion of the analysis. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov NCT06452602. Registered 06/11/2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.